Open company graph database — free web & API
Login

Rekmed Co., Ltd.

株式会社レクメド
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
23
Related companies
8
§01

Basic information

BASIC
Head office
2nd Floor, Daiju Seimei Tokorozawa Building, 1-7-23 Morino, Machida City, Tokyo 194-0022, Japan
Chief executive
Masaharu Matsumoto
Capital
Employees (non-consolidated)
23 people
Employees (consolidated)
Start date
1998-05-12
End date
§02

Websites

1 DOMAINS
§03

Business

4
Pharmaceutical DevelopmentPharmaceutical SalesDevelopment PipelineConsulting
§04

Related companies

8 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
ファイブロジェン
Alliance
Bene Corporation
Alliance
Taisho Pharmaceutical Co., Ltd.
Alliance
Asahi Kasei Pharma Corporation
Alliance
Oji Holdings Co., Ltd.
Alliance Shareholder
Mizuho Bank, Ltd.
Bank
Mitsubishi UFJ Bank Ltd.
Bank
Yokohama Bank Co., Ltd.
Bank
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

36 EVENTS

Established by Kyowa Hakko Kogyo Co., Ltd. and Matsumoto with the purpose of supporting faster development of pharmaceuticals demanded by patients.Sources

PR: Kyowa Fermentation Industry Co., Ltd.Sources

Newspaper: Nikkan Kōgyō Shinbun: "Dream of Reverse Import": Kyowa Fermentation Industry's internal venture, fully financially independent: Introduced new drug candidate substance to companies.Sources

Newspaper: Kagaku Kōgyō Nippō: Strengthening new drug exploration support: Providing optimal information by theme, etc. Also has an activity base in the US.Sources

Newspaper: Yakiji Nippō: Venture-supporting venture company: Already fully independent, what Rekmed aims for.Sources

Magazine: Weekly Toyo Keizai p.93: Feature "Genome Business Blooming": Joint development partnership introduced by Rekmed (US bio-venture Fiverogen Inc.)Sources

Newspaper: Nikkan Kōgyō Shinbun: Signed contract on clinical development introduced by Rekmed (US bio-venture Epigenesis Inc.)Sources

Magazine: Seimei to Kusuri Kaigō Vol. 16, No.2 p.5: Entrepreneurship: New Consultation: Coordination in pharmaceutical development.Sources

Magazine: Weekly Toyo Keizai No.5629 p.28-31: Career Up White Paper 2000: Career Up Advice: Research projects and investment, equal with large companies.Sources

Newspaper: Nikkei Sangyō Shinbun: Opened incubation facility in the US.Sources

Signed a joint development agreement with PsychoGenics, Inc. and Elutoprin.Sources

Signed a joint development agreement with bene pharmaChem GmbH & Co. KG and Pentosan.Sources

Pentosan commenced domestic Phase I clinical trials.Sources

Elutoprin initiated pharmacokinetic studies in Japanese subjects in the United States.Sources

Magazine: BioScience and Industry 2009 vol.67 No.5 p.213-218: Industry and Administration: First Intercollege Bio Leaders event: Through Rekmed, partnered with US Arena Inc.Sources

Magazine: Journal of Biological Engineering, Special Issue 2009, No.5 p.109-110: Come to Intercollege Bio Leaders: First Intercollege Bio Leaders.Sources

Newspaper: Nikkan Yakugyō: METI's research meeting on strengthening international competitiveness: METI decided to establish the "Bio Innovation Research Group" to examine measures to strengthen international competitiveness of the pharmaceutical industry, and held the first meeting on the 16th. (Rekmed President Masato Matsumoto appointed as a member)Sources

Compliance: The first meeting was held on November 16, 2009. As a member (17 members), Rekmed President Masato Matsumoto was appointed.Sources

Pentosan started a preliminary Phase II clinical trial for OA in Japan.Sources

Signed a licensing agreement with Chong Kun Dang Pharmaceutical Corp. for Pentosan in South Korea.Sources

Selected as a development company for betaine, a development support item under the Ministry of Health, Labour and Welfare's unapproved drug development support program.Sources

Betaine received orphan designation from the Ministry of Health, Labour and Welfare.Sources

Signed a licensing agreement with Orphan Europe SARL to obtain exclusive development and sales rights for betaine in Japan.Sources

Obtained a license for the manufacturing and sale of type I pharmaceuticals.Sources

Obtained manufacturing and sales approval for 'Systadan® Original Powder' (generic name: betaine), a treatment for homocystinuria.Sources

Released 'Systadan® Original Powder'.Sources

Pentosan commenced a preliminary Phase II clinical trial for HTLV-1-associated myelopathy (HAM).Sources

Pentosan started a pediatric safety study for mucopolysaccharidosis (MPS).Sources

Pentosan initiated Phase II trials for mucopolysaccharidosis and mucolipidosis.Sources

Signed a licensing agreement with Icahn School of Medicine at Mount Sinai for Pentosan (mucopolysaccharidosis).Sources

Commenced domestic Phase III clinical trial of cholestyramine.Sources

Cholestyramine receives orphan drug designation from the Ministry of Health, Labour and Welfare.Sources

Commenced late Phase II clinical trial of Pentosan for osteoarthritis in Japan.Sources

Transferred Cystatdan® raw material to Recoldata Rare Diseases Japan Co., Ltd.Sources

Obtained domestic manufacturing and sales approval for the treatment drug "Ofacoral® Capsule 50 mg" (generic name: cholestyramine).Sources

Released Ofacoral® Capsule 50 mg.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information8012301002732
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社レクメド
Trade name (kana)
レクメド
Name in English
Corporation type
301
Address
〒194-0022 東京都町田市森野1丁目7番23号
Postal code
1940022
Prefecture code
13
City code
209
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-07-17
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
2433134
METI gBizINFO8012301002732
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
8012301002732
Trade name
株式会社レクメド
Trade name (kana)
レクメド
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都町田市森野1丁目7番23号
Postal code
1940022
Prefecture
東京都
Prefecture code
13
City or district
町田市
City code
209
Street address
森野1丁目7番23号
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
Capital
Employees
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-07-17
Key information
8012301002732
§09

Sources & updates

SOURCES
↑